Companies · Biotechnology

On-Q-ity, Inc.

WALTHAM · Biotechnology

Diligence memoA one-page analyst read on On-Q-ity, Inc. — recommendation, valuation, rhythm, risks.→
$2.5M
Total raised · real
1
Rounds
—
Latest step-up
Top 70%
Sector rank · raised
Seed
Latest stage · inferred · Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

On-Q-ity, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.28× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
  • Within the normal band (128% of peer median) for its niche.
Dormant
  • Last raise 14.4 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

On-Q-ity, Inc. is one of 4293 Biotechnology companies tracked from WALTHAM. By capital raised it ranks in the long tail (ahead of 31% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2012-02-14 Raised $2.5M (real) Modeled valuation $111M (est)$2.5M$111MSeed2012

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.5M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$111.0M
Base estimate est.
$1.8M
Conservative case
$871.0M
Upside case
$12.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
14.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
14.6 yr
On record since
2012
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.3× of median
This company$2.5M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage)▲ 1.4× above median
This company$2.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages)▲ 1.7× above median
This company$111.0M
Sector median$64.2M

Raised more than 31% of sector peers (real $). Modeled value above 61% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #49 of 151.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0MCapital raised (log)Denali Medical II, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Signum Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Health Elements, LLC · Seed Raised $4.0M · modeled $177.6M (est)Nkt Therapeutics Inc · Seed Raised $4.0M · modeled $177.6M (est)Surface Logix Inc · Seed Raised $4.0M · modeled $177.6M (est)Fe3 Medical, Inc. · Seed Raised $5.4M · modeled $177.1M (est)Proteonomix, Inc. · Seed Raised $3.8M · modeled $169.0M (est)SRS Medical Systems, Inc. · Seed Raised $3.8M · modeled $167.4M (est)Origen Therapeutics Inc /Ca · Seed Raised $3.7M · modeled $166.2M (est)Vivebio, LLC · Seed Raised $3.7M · modeled $163.1M (est)O2 Medtech Inc · Seed Raised $7.1M · modeled $160.3M (est)Biothera, Inc. · Seed Raised $3.5M · modeled $155.4M (est)On-Q-ity, Inc. (this company) Raised $2.5M · modeled $111.0M (est)On-Q-ity, Inc.
CompanyStageRaised · realValue · estvs peer med.
Denali Medical II, Inc.Seed$4.0M$177.6M2.05×
Signum Biosciences, Inc.Seed$4.0M$177.6M2.05×
Health Elements, LLCSeed$4.0M$177.6M2.05×
Nkt Therapeutics IncSeed$4.0M$177.6M2.05×
Surface Logix IncSeed$4.0M$177.6M2.05×
Fe3 Medical, Inc.Seed$5.4M$177.1M2.05×
Proteonomix, Inc.Seed$3.8M$169.0M1.95×
SRS Medical Systems, Inc.Seed$3.8M$167.4M1.93×
Origen Therapeutics Inc /CaSeed$3.7M$166.2M1.92×
Vivebio, LLCSeed$3.7M$163.1M1.88×
O2 Medtech IncSeed$7.1M$160.3M1.85×
Biothera, Inc.Seed$3.5M$155.4M1.79×
On-Q-ity, Inc. this companySeed$2.5M$111.0M1.28×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.5M2012-02-14$12.5M$111.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.5M2012-02-14
    • First recorded raise — entered as Seed.
Intelligence
—
Modeled next raise
$4.0M
Modeled next size est.range $2.6M–$6.4M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
ROBERT S. EPSTEIN—2 other2012-02
Bruce T. Booth——2012-02
Dion T. Madsen——2012-02
Michael T. Stocum——2012-02
Stephen S. Kraus——2012-02
Sue T. Siegel——2012-02
Registry & provenance

On-Q-ity, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1543182
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Amnion Life LLCBiotechnologySeed$2.5M$111.0Msame sector · same stage
Polybiomics Inc.BiotechnologySeed$2.5M$111.0Msame sector · same stage
Progentec Diagnostics, Inc.BiotechnologySeed$2.5M$111.0Msame sector · same stage
Tabashir Health LLCBiotechnologySeed$2.5M$111.0Msame sector · same stage
Therapeutic Proteins IncBiotechnologySeed$2.5M$111.0Msame sector · same stage
Trelys, Inc.BiotechnologySeed$2.5M$111.0Msame sector · same stage
Cellective BioTherapy, Inc.BiotechnologySeed$2.5M$111.0Msame sector · same stage
entrotech life sciences, inc.BiotechnologySeed$2.5M$111.0Msame sector · same stage
Frequently asked
How much funding has On-Q-ity, Inc. raised?
On-Q-ity, Inc. has raised approximately $2.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is On-Q-ity, Inc.'s estimated valuation?
Provath's modeled valuation for On-Q-ity, Inc. is approximately $111.0M (modeled range $1.8M–$871.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is On-Q-ity, Inc. at?
On-Q-ity, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Tue Feb 14.
What does On-Q-ity, Inc. do and where is it based?
On-Q-ity, Inc. operates in the Biotechnology sector, based in WALTHAM.
Explore related

See where On-Q-ity, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at On-Q-ity, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.